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A B S T R A C T
Current diagnostic tests for Mycobacterium tuberculosis (MTB) infection have low prognostic specificity for
identifying individuals who will develop tuberculosis (TB) disease, making mass preventive therapy strategies
targeting all MTB-infected individuals impractical in high-burden TB countries. Here we discuss general con-
siderations for a risk-targeted test-and-treat strategy based on a highly specific transcriptomic biomarker that
can identify individuals who are most likely to progress to active TB disease as well as individuals with TB
disease who have not yet presented for medical care. Such risk-targeted strategies may offer a rapid, ethical and
cost-effective path towards decreasing the burden of TB disease and interrupting transmission and would also be
critical to achieving TB elimination in countries nearing elimination. We also discuss design considerations for a
Correlate of Risk Targeted Intervention Study (CORTIS), which could provide proof-of-concept for the strategy.
One such study in South Africa is currently enrolling 1500 high-risk and 1700 low-risk individuals, as defined by
biomarker status, and is randomizing high-risk participants to TB preventive therapy or standard of care
treatment. All participants are monitored for progression to active TB with primary objectives to assess efficacy
of the treatment and performance of the biomarker.
1. Introduction
Approximately 1.7 billion individuals worldwide are infected with
Mycobacterium tuberculosis (MTB) [1]. These individuals are identified
by a positive tuberculin skin test (TST) or interferon-gamma release
assay (IGRA) that indicates an MTB-specific immunological response.
Though IGRA/TST-positive individuals have higher risk of developing
TB disease than uninfected individuals [2], the tests have poor
specificity for identifying individuals who will progress to active TB,
since over 95% of IGRA/TST-positive HIV-uninfected and approxi-
mately 70% of IGRA/TST-positive HIV-infected individuals never de-
velop active disease [3,4]. Therefore, although prevention of progres-
sion from infection to TB disease is key to achieving WHO elimination
targets [5], mass preventive therapy based on IGRA/TST screening in
TB endemic countries would need to treat 50–80% of the population,
most of them unnecessarily. Using current commercial IGRAs, such as
https://doi.org/10.1016/j.tube.2017.11.009
Received 15 September 2017; Received in revised form 17 November 2017; Accepted 21 November 2017
∗ Corresponding author.
E-mail addresses: agartlan@fredhutch.org (A. Fiore-Gartland), lcarpp@fredhutch.org (L.N. Carpp), Kogie.Naidoo@caprisa.org (K. Naidoo), daniel.zak@cidresearch.org (D.E. Zak),
sself@fredhutch.org (S. Self), gchurchyard@auruminstitute.org (G. Churchyard), gwalzl@sun.ac.za (G. Walzl), adam.penn-nicholson@uct.ac.za (A. Penn-Nicholson),
thomas.scriba@uct.ac.za (T.J. Scriba), mark.hatherill@uct.ac.za (M. Hatherill).
Abbreviations: 3HP, 12-dose once-weekly rifapentine 900 mg plus isoniazid 900 mg; ACS, Adolescent Cohort Study; COR, correlate of risk; CORTIS, Correlate of Risk Targeted
Intervention Study; IGRA, interferon-gamma release assay; MTB, Mycobacterium tuberculosis; RR, relative risk; TB, tuberculosis; TST, tuberculin skin test
Tuberculosis 109 (2018) 61–68
1472-9792/ © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
T
the QuantiFERON-TB Gold In-Tube test, it has been estimated that 85
persons with latent TB would need to be treated to prevent a single case
of active TB [6], making such an approach neither viable nor cost-ef-
fective. Mass preventive therapy for all MTB-infected people would also
not be effective, since reinfection could occur before programmatic
coverage could be completed. For instance, the Thibela trial enrolled
South African mine workers, 89% of whom were estimated to have
latent MTB infection [7]; the mass test-and-treat strategy in this po-
pulation had no significant effect on TB incidence [8].
A screening tool with greater specificity could identify individuals
with the highest risk of developing TB disease, thereby reducing the
number of people who would be treated needlessly in an IGRA-targeted
treatment campaign. A risk-targeted test-and-treat strategy based on a
highly specific biomarker would also impact the greater epidemic by
identifying and treating persons with infectious TB disease, thereby
interrupting transmission.
MTB infection is associated with a broad clinical spectrum of disease
pathogenesis [9], including an asymptomatic stable quiescent infection
state; an incipient pre-clinical disease state; an asymptomatic, but mi-
crobiologically detectable, subclinical disease; and an active sympto-
matic disease state [6] (Fig. 1). For biomarker evaluation we define TB
disease and TB risk by that which is microbiologically detectable, a
standard for TB diagnosis. One consequence is that many individuals
with TB disease may not have presented for medical care (i.e. the
walking ill), creating the need for two types of cases in the setting of a
clinical trial with active surveillance: (1) Prevalent cases detected at the
beginning of a study are either subclinical or active, but previously
undiagnosed; and (2) Incident cases, which progress to active disease
during follow-up. A biomarker's ability to identify individuals with
prevalent TB (i.e. diagnostic performance) and its ability to predict
which individuals will develop TB (i.e. prognostic performance) may
differ, though both are clinically valuable for TB prevention.
Previously we identified and validated a prognostic blood mRNA
expression signature that could be used in a risk-targeted TB prevention
campaign [10] (correlate of risk, COR). In a prospective cohort of HIV-
uninfected South African adolescents, the COR had 84% specificity
(95% CI 79.1–87.9) and 71% sensitivity (95% CI 55.9–83.1) in com-
bined training and test sets for discriminating between TB progressors
and non-progressors within 12 months of testing [11]. Sensitivity was
greater nearer to the time of TB diagnosis. The COR also displayed
comparable or better performance for discriminating active TB disease
from latent MTB infection in published microarray data from adult
cohorts in the UK, South Africa, and Malawi [10], and in our own
preliminary data (92% sensitivity and 93% specificity for prevalent TB
disease) [11]. These findings demonstrate that the COR is robust to age
and geographic region in its potential to detect prevalent TB, in addi-
tion to its ability to identify persons at risk for developing active (in-
cident) TB disease.
The use of a host biomarker to target high-risk individuals for TB
preventive therapy is a form of personalized medicine similar to blood-
based biomarkers that guide treatment selection decisions in cancer
therapy [12–15]. Risk-targeted treatment is a potential TB control
strategy that can be clinically evaluated with existing treatment selec-
tion paradigms that can be adapted to address the unique challenges of
TB epidemiology, pathophysiology and available interventions [16,17].
For successful risk-targeted treatment, it is important to have both 1) an
efficacious preventative treatment and 2) a good biomarker for se-
lecting high-risk individuals. In treatment selection trial designs, both
factors are evaluated concurrently.
A successful mass campaign to halt TB transmission using a risk-
targeted test-and-treat strategy would require an effective and safe
short-course, sterilizing preventive therapy, such as the 12-dose once-
weekly rifapentine 900 mg plus isoniazid 900 mg (3HP) regimen
[18,19]. This regimen has been shown to be as effective as 9 months of
isoniazid alone at preventing TB disease in latently infected individuals
[19]; however, more data are needed to determine its efficacy in a
biomarker-selected high-risk subgroup and in hyper-endemic settings
with a high force of infection. Before a large cluster randomized trial is
implemented to evaluate population level effects of the strategy, a
proof-of-concept trial is needed to: (1) validate the COR in an un-
selected population, (2) test the efficacy of treating COR+ persons in
reducing incident TB disease, and (3) evaluate the overall value of a
risk-targeted test-and-treat strategy with these operating character-
istics.
Here we discuss general considerations for a proof-of-concept study
and the specific design of the Correlate of Risk Targeted Intervention
Study (CORTIS-01; ClinicalTrials.gov NCT02735590), a clinical trial
currently underway in TB hyper-endemic areas of South Africa.
CORTIS-01 enrols COR+ and COR-individuals and randomizes COR +
individuals to TB prevention therapy (3HP) or standard of care (SOC).
The objective of this manuscript is to provide justification of the
CORTIS-01 trial design and to inform future efforts to design trials of
targeted TB interventions. These considerations become increasingly
important as the results of CORTIS-01 become available and other
biomarkers for TB are developed. Applied at the community level, such
risk-targeted strategies are anticipated to accelerate reduction in TB
incidence and mortality and to reduce the pool of MTB-infected in-
dividuals independently of ongoing improvements in TB vaccines, di-
agnostics, and therapeutics.
Fig. 1. Tuberculosis biomarker comparison. Infection with Mycobacterium tuberculosis
(MTB) is associated with a broad clinical spectrum of pathogenesis that includes
asymptomatic persistent MTB infection; incipient TB disease; asymptomatic, but micro-
biologically detectable, sub-clinical TB disease; and active symptomatic TB disease. In
CORTIS-01 the TB disease endpoint is based on detection of MTB nucleic acid (Xpert
MTB/RIF) and/or sputum culture (Mycobacteria Growth Indicator Tube assays, MGIT), a
standard tool for TB diagnosis. The interferon gamma release assay (IGRA) and the tu-
berculin skin test (TST) detect MTB-specific T cells in the blood and are currently used to
identify MTB-infected individuals. Most IGRA/TST+ individuals will not develop active
disease. The COR is an mRNA expression signature that detects the type I/II interferon
response and is associated with active disease (i.e. diagnostic) and with individuals who
are likely to develop disease (i.e. prognostic). A test-and-treat strategy would treat only
COR+ individuals to prevent active disease. Individuals with latent MTB infection that
have a lower risk of developing active TB disease may be IGRA/TST+ and COR-, thus
sparing them unnecessary treatment in a mass test-and-treat campaign.
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2. General design considerations for evaluating screen and treat
strategies
Several clinical trial designs have emerged for evaluating the ben-
efits of biomarkers employed in treatment selection strategies in cancer
and personalized medicine [16]. Under the gold standard trial design
all participants are randomized to treatment or no treatment, regardless
of biomarker status. In the context of TB prevention, such a design
would enroll four groups of participants, where COR ± denotes TB risk
status based on a dichotomous COR biomarker: (1) Treated, COR−, (2)
Untreated, COR−, (3) Treated, COR+, and (4) Untreated, COR+ (Fig.
S2). The scientific advantage of this design is that treatment efficacy
can be directly compared in high and low risk populations, and post hoc
analyses can be used to optimize a biomarker threshold or to compare
different biomarkers head-to-head (e.g. an IGRA), since all participants
are subject to randomization. The specific proportions of COR+ and
COR− participants enrolled in a given trial have important logistical
and ethical implications for the conduct of the trial. For example, en-
rolling and randomizing all members of a community to treatment is
both logistically challenging and ethically problematic since it would
require following and treating large numbers of low-risk COR− parti-
cipants, who are unlikely to receive any benefit from treatment, while
being subject to its risks. To address this limitation, three alternative
clinical trial designs have emerged in the cancer field for evaluation of
biomarker-guided therapy [20].
An “enrichment design” would enrol only high-risk individuals that
are COR+ and randomize participants to treatment or no treatment.
This design enables evaluation of treatment efficacy in a high-risk
subgroup and benefits from a much smaller sample size, however it
precludes evaluation of biomarker performance, since COR− partici-
pants are not enrolled.
In a “biomarker strategy” design, the test-and-treat strategy is ran-
domized to study participants; participants in one group are provided
the standard of care (SOC, i.e. no risk-targeted treatment strategy)
while participants in the other are provided treatment based on their
biomarker status (i.e. treatment for COR+ only). This design enables
direct evaluation of the efficacy of the test and treat strategy in com-
parison to the SOC. In the context of TB it could also be implemented as
a community-based cluster randomization of the strategy to capture
indirect effects like transmission reduction or knowledge of COR status.
Such cluster randomized trials would also potentially be more feasible
in the real-world setting. However, like the fully randomized trial, a
large fraction of enrolled participants contribute very little information
to estimates of treatment efficacy, which refers to the relative reduction
in risk in treated compared to untreated COR+ participants; COR−
participants enrolled in both the SOC and intervention arm may even be
redundant.
Finally, a “hybrid” design is an enrichment design that additionally
includes a limited biomarker-negative group to gain information about
biomarker performance. This design affords randomized assessment of
treatment efficacy, efficient estimation of biomarker performance, and
preliminary estimates of strategy efficacy. The design does not permit
the comparison of test-and-treat strategies using different biomarkers
(e.g. IGRA vs. COR), since a given participant can only be re-
commended for treatment using one biomarker. However, a direct
comparison can be made of the biomarkers' abilities to discriminate TB
progressors from non-progressors. The most appropriate design would
also depend on the prevalence and performance of the biomarker in the
target population and the strength of the evidence indicating that only
the biomarker-positive subgroup will benefit from the treatment
[21,22]. The challenge of TB control in high transmission settings is the
high prevalence of latent MTB infection and the low proportion that
progress to TB disease, which calls for innovative and expeditious de-
signs. Considering these factors, CORTIS-01 was based on a hybrid
design.
3. Ethical considerations
The basic underpinning of the ethical considerations for any clinical
trial is that the potential benefits outweigh the potential risks for each
participant and thus a hybrid design in which COR+ individuals pre-
dicted to be at higher risk of TB disease are not allocated treatment is
potentially contentious. In countries such as South Africa where there is
a high TB burden and the majority of adults have latent MTB infection
(defined by a positive IGRA or TST), the protective benefits of therapy
for latent MTB infection are transient, and limited to the fraction of
recipients that will progress to TB disease during their lifetime. The
risks of therapy are substantial and potentially include treatment in-
tolerance, hepatoxicity and a high pill burden. Accordingly, treatment
of latent MTB infection is not the SOC for TST or IGRA positive in-
dividuals in South Africa, except for children under the age of five, HIV-
infected persons and people with silicosis [23]. We hypothesize that the
COR has better prognostic specificity for TB disease than IGRA/TST, but
like IGRA/TST, most COR+ individuals will remain disease-free and
would not benefit from preventative therapy. Individuals with “false
positive” COR+ status would thus only be exposed to the potential risk
of preventative therapy, not its benefits. Therefore, it is important to
consider the body of knowledge about a biomarker and the precision of
its performance in the study population. Estimates of COR prognostic
performance are based on two nested case-control studies (n = 46
progressors and 107 matched controls from the Adolescent Cohort
Study (ACS) [24] and n = 73 progressors and 301 controls from the
GC6 household contact study [10]); COR performance has never been
validated in a prospective cohort. Thus, individual risk of COR+ status
is not yet known. Moreover, COR performance may differ in cohorts
differing in age or geography. There is also uncertainty in how COR+
individuals will respond to preventative therapy, since its benefit has
not been demonstrated in this biomarker-defined subgroup. Since the
COR seems to identify participants with incipient TB disease, it is
possible that the regimen will not be as effective at preventing disease
progression as it is in clearing a latent infection, which may reduce
treatment efficacy in COR+ individuals. COR+ individuals may also be
more likely to have risk factors for TB disease such as a weakened
immune response, which may also reduce treatment efficacy. It is
possible that COR+ individuals require a full course of 4-drug curative
TB treatment rather than 3HP to prevent progression to disease, but
evidence of (1) good prognostic COR performance, and (2) poor effi-
cacy of 3HP preventative therapy would be needed to justify such a
major intervention for otherwise healthy people. With knowledge of
biomarker performance and treatment efficacy, the number of bio-
marker-targeted treatments needed to avert one case is critical in
finding the balance of potential risks and benefits to participants. Based
on the cumulative knowledge and uncertainty summarized above we
believe there is equipoise for the CORTIS-01 design and we are hopeful
that the results will provide more knowledge for the design of future
studies and interventions.
It is possible that the biomarker will perform so well that it is
ethically imperative to provide immediate treatment to all COR+ par-
ticipants before the end of follow up. If the study treatment is demon-
strating sufficient efficacy then it could be provided to all COR+ par-
ticipants, otherwise a more rigorous therapeutic regimen could be
recommended. Planning an unblinded interim analysis of treatment
efficacy and biomarker performance protects participant welfare in
these scenarios. Such an analysis can also be used to halt the trial for
futility if low rates of TB or low biomarker performance precludes the
possibility of meeting any of the study objectives. Ideally the analysis
would assess appropriate stopping thresholds for biomarker perfor-
mance and treatment efficacy and would be triggered by a pre-specified
total number of TB cases that would provide sufficient power to detect
these outlier scenarios (see Supplement).
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4. CORTIS considerations
4.1. CORTIS objectives
The three fundamental objectives of a CORTIS are to: (1) Evaluate
the diagnostic performance of the COR for identifying prevalent TB
disease and the prognostic performance of the COR for predicting in-
cident TB disease, (2) Evaluate the efficacy of the treatment regimen (in
CORTIS-01, the short-course 3HP treatment regimen) to reduce in-
cident TB in COR+ participants, and (3) Evaluate the efficacy of the
test-and-treat strategy in the study population as a whole. Each objec-
tive relies on the comparison of TB risk in two comparator groups
(Fig. 2).
Biomarker performance can be evaluated by comparing the relative
risk of TB disease among COR+ versus COR− participants (RRCOR)
while receiving the SOC (i.e. active surveillance for symptomatic TB);
this can be computed based on prevalent or incident TB for evaluating
diagnostic or prognostic performance, respectively. Treatment efficacy
is the relative reduction in TB incidence in treated COR+ compared to
untreated (i.e. receiving the SOC) COR+ participants; treatment effi-
cacy may be different in COR+ individuals compared to IGRA+ in-
dividuals for the reasons discussed above. The efficacy of the test-and-
treat strategy is determined by estimating the relative reduction in TB
incidence in the entire study population had all COR+ participants been
provided the treatment compared to a study population that had not
received any risk-targeted treatment. To make these comparisons for all
three objectives, at least three groups of participants need to be en-
rolled, evaluated for prevalent TB at baseline, and followed by active
surveillance for incident TB disease: COR+(Rx), randomized to treat-
ment; COR+(SOC), randomized to SOC only; and COR−(SOC), pro-
vided SOC only.
A hybrid trial designed with only these groups has certain limita-
tions. For instance, without including a placebo for evaluation of
treatment efficacy, estimates could be biased by knowledge of treat-
ment assignment or knowledge of COR status, if only one of the groups
has such knowledge. For example, knowledge of COR status or treat-
ment could influence a participant's behavior and also their TB risk, but
including such behavior modifications in the estimation of the treat-
ment effect is permissible because it would also presumably affect a
real-world strategy implementation. Similarly, for estimation of RRCOR,
knowledge of COR status by either COR− or COR+ participants could
introduce bias. For CORTIS-01 we chose not to use a placebo, but in-
stead enrolled an untreated COR+ group assigned to SOC active sur-
veillance, and double-blinded to COR status [this is achieved
Fig. 2. “Hybrid” treatment selection design for CORTIS-
01. (A) Healthy, HIV-uninfected adults are recruited and
screened using the COR blood-based biomarker. Within 28
days of screening, COR+ participants are enrolled and ran-
domized to preventive therapy (Treatment/Rx) or standard of
care (SOC). A fraction (F) of COR− participants are enrolled
in a SOC arm. All enrolled participants are followed for 15
months for TB disease. COR+ and COR− participants are
enrolled concurrently and therefore rate of enrolment directly
depends on the prevalence of COR-positivity (π0). (B) The
rate of incident TB in the COR+(Rx) and COR+(SOC) groups
can be compared to evaluate treatment efficacy, while com-
parison of the COR+(SOC) and COR−(SOC) groups yields
information about biomarker performance. Strategy efficacy
is assessed using all three groups.
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operationally by blinding all site staff and participants to COR status
with the exception of participants in the COR+(Rx) group]; the group
can be shared for estimation of treatment efficacy and RRCOR. While
there is potential for knowledge of open-label treatment and COR+
status in the COR+(Rx) group to affect treatment efficacy and strategy
efficacy estimation, it is permissible for these effects to be included, as
they would also contribute to overall effectiveness. We have also con-
sidered that knowledge of COR+ and open-label treatment status might
introduce investigator ascertainment bias of TB cases. In order to
minimize this potential bias, we ensure that different site staff are re-
sponsible for dispensing therapy and collecting TB symptom data,
which would trigger an investigation for TB endpoint determination.
Moreover, TB screening at study visits is the same in all arms to avoid
differences in ascertainment of TB cases. The advantage of a three-arm
trial is a substantial increase in statistical power per participant, since
participants and TB endpoints are effectively shared across the three
objectives. This highly efficient trial design allows substantial savings in
study resources, duration, and cost, since fewer total participants are
required. Group sizes can be further optimized, based on hybrid design
simulations described below, to reduce the fraction of COR− in-
dividuals enrolled.
4.2. TB endpoint assessment
The CORTIS-01 TB disease endpoint is based on the detection of
MTB nucleic acid (Xpert MTB/RIF) and/or culture (Mycobacteria
Growth Indicator Tube assays), requiring two positive results of either
test from two serially-collected sputum samples. At enrolment, two
sputum samples are collected from all participants able to produce
sputum for Xpert MTB/RIF and/or culture; thereafter presence of
compatible symptoms triggers investigation for TB during follow-up.
Finally, all sputum-productive participants are tested again at end of
study to detect any cases of sub-clinical disease (Fig. 1). We defined
prevalent TB cases as those detected at the first (enrolment) study visit
with all others defined as incident TB. We separately evaluate the COR
as a prognostic biomarker of progression to incident disease and as a
diagnostic biomarker of prevalent TB disease. In the future, a biomarker
with both prognostic and diagnostic utility might even leverage two
different triage test thresholds, one to trigger investigation for active
disease and another for provision of treatment of infection (Fig. S1A).
This additional capability would be a substantial benefit to a test-and-
treat program.
The evaluation of COR performance and strategy efficacy could also
include both prevalent and incident TB cases, since both are examples
of undetected TB in the community that could benefit from detection
and treatment. Evaluation of treatment efficacy will be conducted only
on incident TB (i.e. a modified intent-to-treat analysis), as TB cases
diagnosed at baseline will be withdrawn from the study and referred for
curative therapy.
4.3. Biomarker operationalization
In preparation for CORTIS, we established high-throughput, auto-
mated standard operating procedures for the PAXgene whole blood
RNA extraction and refined microfluidic multiplex qRT-PCR (Fluidigm
BioMark HD platform) steps to simultaneously measure the COR sig-
nature in 94 samples, plus a no-template control and a standardized
internal positive control (IPC) sample. The locked down analysis script
includes quality control (QC) filters for exclusion of individual samples,
single transcripts or entire qRT-PCR runs, should they be flagged de-
viating from pre-defined criteria. Robustness of COR performance was
assessed, including evaluation of assay accuracy and precision and
measurement of inter -assay, intra-assay and inter-operator variance.
The COR assay had excellent repeatability and reproducibility, while
also incorporating a standardized IPC sample into each qRT-PCR run,
which must meet pre-specified performance targets (see Supplement).
The COR assay displays robust performance and reliable interpretation
even at scale, enabling centralized laboratory testing of> 400 samples
per week.
4.4. Biomarker performance estimation for study simulations
For the design of CORTIS-01 it was important to consider that the
ability of the COR to predict TB progression was higher when the COR
was measured more proximally to TB diagnosis. In other words, the
CORs ability to predict incident TB decreases over time, with a sub-
stantial decrease in performance after 18 months have elapsed [10]. We
hypothesize that this decay in COR performance over time is related to
the strength of the interferon response, which is more pronounced at
sampling times proximal to active TB disease [25]. In the CORTIS we
expect that a COR measured at baseline will be more effective at pre-
dicting incident TB earlier in the follow-up period; TB progression later
in the follow-up period may be equally likely in participants who were
COR+ or COR− at baseline. Therefore, cumulative estimates of COR
performance and strategy efficacy may decline with longer follow-up
durations. However, the duration of follow-up must be sufficient to
estimate the durability of treatment efficacy and to demonstrate the
ability of the COR to predict development of active TB in the future.
These factors directly impact the durability of the overall strategy,
which will be an important criterion for an efficient and effective mass
test-and-treat campaign.
To precisely estimate COR performance over time we re-analyzed
data collected in the ACS [24] (see Supplement). We estimated the
hazard ratio (HR) curve over time: the relative risk of COR+ versus
COR− participants (Fig. 3A). The shape of the HR curve was consistent
with previous findings: at baseline, COR+ participants were 15-fold
Fig. 3. Performance characteristics of
COR biomarker. The COR was measured at
baseline in participants of the Adolescent
Cohort Study (ACS). (A) Relative risk of
developing TB disease for COR+ vs. COR−
participants was computed longitudinally
using a cumulative incidence-based ap-
proach (blue shaded 95% confidence in-
terval from bootstrap sampling). Data was
approximated well by exponential decay
from RR = 15 to RR = 1 with decay time
constant of 12 months (dashed line). (B)
Sensitivity (red) and specificity (blue) of
COR in the ACS training and test set samples
up to 1 year preceding TB disease.
Classification performance depends on the
threshold applied to the continuous readout.
Using a 60% threshold, the COR had 71%
sensitivity and 84% specificity.
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more likely to progress to active TB, and their relative risk for pro-
gression declined over time. The apparent increase in HR after 24
months is an artefact, due to a sharp decrease in the number of at-risk
participants near study end. The HR curve was approximated well by an
exponential decay model with a decay time-constant of 12 months.
Since the original study included only IGRA+ individuals, we also
measured the COR in 100 IGRA− individuals; reported results reflect a
re-weighting for translation to a mixed IGRA ± population.
Multiple HR curves were estimated using a range of biomarker
thresholds for determining COR positivity. An optimal threshold of 60%
was selected for the trial, due to the relatively high sensitivity/speci-
ficity (Fig. 3B) and the estimated 15% population prevalence of COR+
individuals (Fig. S1B), which would be a reasonable target population
for implementation of a test-and-treat program. We note that the choice
of a relatively low COR threshold also provides more flexibility for post
hoc analyses in the CORTIS trial that evaluate the impact of higher test
thresholds on diagnostic and prognostic performance. A higher COR
threshold does not allow for post hoc analyses of a hypothetical lower
threshold, since participants with a COR below the actual threshold
would not have been randomized to the COR+ groups.
4.5. CORTIS objective evaluation
Each CORTIS objective requires a specific hypothesis and accom-
panying statistical test. Studies employing a time-to-event endpoint,
such as TB progression, commonly hypothesize that the endpoint rate is
different in two comparator groups and test this using a Cox propor-
tional hazards regression [26]. For example, one could evaluate COR
performance by comparing the rate of incident TB in COR+ versus
COR− groups (both untreated) and testing for a significant difference
with a Cox model. Interpretation of the coefficients derived from a Cox
regression and their significance requires the assumption that TB in-
cidence is proportional in the two groups, yet relative risk of COR+ and
COR− participants' changes over time (Fig. 3A), thus falsifying this
assumption. Therefore, we elected to use cumulative incidence-based
statistics for the estimation of treatment efficacy, RRCOR and strategy
efficacy, as they are not constrained by this assumption. These methods
accommodate time-varying effects, allowing for visual assessment of
the changes over time, as well as a direct test of the cumulative effect at
the end of follow-up. Ultimately, it is the cumulative performance of the
biomarker and the cumulative effect of treatment that are relevant for
the implementation of a test-and-treat program; only a biomarker and
treatment with long lasting effects will be clinically useful and meet the
desired characteristics required for an effective mass campaign [6,27].
Considerations for choosing follow-up duration include the need to
assess treatment efficacy durability and the need to obtain precise es-
timates of the exponential decay in COR prognostic value.
Trials often test a null hypothesis of “no effect” as the lowest bar for
establishing statistical significance. In CORTIS-01, we test more strin-
gent hypotheses for treatment efficacy and COR performance to ensure
that a statistically significant result is also clinically relevant. For COR
performance, we defined a null hypothesis requiring that the cumula-
tive relative risk of untreated COR+ versus COR− participants over 15
months (RRCOR(15)) is greater than 2 (two-sided, α = 0.05) (see
Supplement). In addition to using RR(15), biomarker performance can
be assessed using time-dependent estimates of sensitivity, specificity,
positive predictive value, and number needed to treat [28]. Though
cumulative effects may have the greatest impact on policy, monitoring
these metrics longitudinally will offer important insights into the un-
derlying pathogenesis and inform implementation of future risk-tar-
geted prevention strategies. For treatment efficacy we require that cu-
mulative efficacy over 15 months (TE(15)) is greater than 20%,
however we use α = 0.1 (two-sided); relaxing the α-level is justified
because previous studies have demonstrated the efficacy of the 3HP
regimen for preventing TB disease and because less precision is required
in this proof-of-concept study. A more definitive trial might require the
more canonical α = 0.05.
To evaluate strategy efficacy, one would ideally compare cumula-
tive incidence in two populations, each with a mixture of COR ± status,
only one of which is provided COR+ targeted therapy. Though these
two groups do not exist explicitly, as a consequence of the “hybrid”
design, they can be recreated in silico by sharing the COR− group and
scaling each COR+ group to the total COR prevalence (see
Supplement). For strategy efficacy we use a more standard null hy-
pothesis of no effect (α = 0.1, two-sided); the lower α-level is justified
as the objective is to provide a preliminary estimate and demonstrate
proof-of-concept for this novel prevention strategy.
4.6. Statistical power
To determine the number of participants that would be needed, we
simulated trials using different group sizes and identified options with
adequate power for the primary objectives (see Supplement for simu-
lation details). Two operational parameters can be modified to alter the
number of participants in each group: (1) the treatment randomization
ratio (K) and (2) the fraction of screened COR− participants to enrol
(F). Though power can be increased overall by screening and enrolling
more participants, a balance of power for all objectives is desirable. For
example, we found that while randomizing more COR+ participants to
treatment increased power for treatment efficacy, it reduced the total
number of endpoints, tending to reduce power for RRCOR. In future
studies, if treatment efficacy has been well established, group sizes
could be rebalanced to deemphasize the treatment efficacy objective.
Decreasing the number of COR− participants enrolled had little impact
on power for RRCOR and strategy efficacy, until the number of projected
endpoints was too low for precise estimates of incidence. Determining
the duration of follow-up is complex, because as TB cases accrue over
time, precision of treatment efficacy increases, but as RRCOR wanes,
power for detecting significant cumulative RRCOR and strategy efficacy
declines.
We determined that 1500 COR+ and 1700 COR− participants
should be enrolled and followed for 15 months and 500 COR+ parti-
cipants should be provided 3HP preventive therapy (K= 0.5). Based on
an estimated COR prevalence of 15% (Fig. S1B), this would require
screening approximately 10,000 HIV-uninfected individuals, with 6800
COR− individuals who would be eligible but not enrolled (F = 0.2).
One operational challenge is that COR prevalence directly impacts the
rate of enrolment and the total number of individuals who would need
to be screened. Lower than expected COR prevalence may indicate
greater biomarker specificity, however it creates a logistical challenge
of having to screen more volunteers. Obtaining accurate knowledge of
COR prevalence in the target population is critical to success. From the
simulations we can estimate Kaplan-Meier “survival” curves for the TB
endpoint in each group (Fig. 4A) and compute power for each objective.
The study is designed to have 81% power for detecting significant
treatment efficacy, 92% power for establishing a RRCOR>2 and 30%
power for detecting significant strategy efficacy (Fig. 4B; see
Supplement). This balance reflects the relative importance of the ob-
jectives as well as the necessarily lower power for strategy efficacy,
which was deemed an exploratory objective. In our simulations, power
is relatively robust to reduction in follow-up, however the benefits of a
lower cost and more expedient study need to be weighed against the
loss of information about the durability of treatment efficacy and bio-
marker performance.
5. Implications and future directions
For future long-term country-wide strategies in which people un-
dergo repeated (e.g. annual) COR testing to be realized, within-person
COR variation will need to be characterized longitudinally. This is
particularly relevant for COR+ participants who do not develop disease,
as these represent false-positives that limit biomarker specificity.
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Longitudinal assessments could show that for these cases initial posi-
tivity was transient, possibly mediated by a non-TB induced interferon
response (though we have shown that the COR differentiates TB disease
from lung cancer, sarcoidosis, and pneumonia [10]). Longitudinal
variation would also be relevant for understanding COR− participants,
as they would be tested regularly in a long-term strategy. Since COR
performance at predicting active disease increases as the time of diag-
nosis approaches [10], it may be that repeated COR assessments have
greater performance as latently infected individuals progress to active
disease. A CORTIS with repeated longitudinal COR measurements could
provide insight into these issues [29]. Future trials might also assess the
performance of the COR to detect post-treatment recurrence, which
ranges from 2 to 10% in hyperendemic communities [30–33], or as a
correlate of treatment response [10,34,35]. Future implementation
studies could also be designed to estimate cost savings or adverse event
reduction by comparing cost/adverse events of the biomarker-based
test-and-treat strategy with those of alternative strategies. A final con-
sideration is how HIV-infected individuals could be screened using the
COR. In a pilot study, we determined that performance of the COR for
discriminating prevalent TB disease from latent TB infection was 13%
lower in HIV-infected individuals than in HIV-uninfected individuals
(data not shown). We hypothesize that the reduced diagnostic perfor-
mance may be attributed to the type I interferon signature observed in
chronic HIV infection [36,37]; it may thus be necessary to adjust the
COR to account for HIV status to provide risk-targeted therapy to HIV-
infected individuals.
The CORTIS design could be relevant to future trials aimed at other
infectious diseases with relevant epidemiological and pathogenic fea-
tures. For example, only about 20–30% of individuals infected with
Trypanosoma cruzi develop active Chagas disease and current drugs for
treating T. cruzi infection are highly toxic [38]. A CORTIS design could
help identify and treat only individuals with the highest risk of pro-
gressing to disease, pending development of a drug regimen with de-
monstrated efficacy.
6. Conclusions
The CORTIS design addresses critical needs for the implementation
of risk-targeted test-and-treat strategies by 1) evaluating the COR as a
prognostic test for incident disease; 2) evaluating the efficacy of pre-
ventive therapy in COR+ individuals, and 3) providing a preliminary
assessment of a test-and-treat strategy. The ethical and technical
Fig. 4. Simulated TB endpoints. CORTIS-01 was simulated
stochastically 10 K times using parameters estimated from
previous observation studies, including overall TB incidence
of 1.1 cases per year, treatment efficacy of 80% and an initial
COR relative-risk of 15, decreasing exponentially to 1 with
decay constant of 12 months (see Supplement). (A) Kaplan-
Meier survival curves and the associated 2.5th and 97.5th
percentiles across simulations for the COR+(Rx) group (red),
the COR+(SOC) group (blue) and the COR−(SOC) group
(green) within each trial. (B) Power to detect statistically
significant treatment efficacy (TE ≥ 20%; two-sided α = 0.1;
blue line), relative-risk (RRCOR ≥ 2; two-sided α = 0.05; red
line) and strategy efficacy (SE ≥ 0%; two-sided α = 0.1;
black line) was computed as the fraction of simulated trials in
which a significant effect was detected.
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considerations discussed here may be relevant to the design of future
trials of risk-targeted TB interventions as improved TB biomarkers are
validated and may also provide a framework within which the CORTIS-
01 results can be interpreted as they become available.
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